Serum metabolomic profiling and incident ckd among african americans

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 8, 2014, Pages 1410-1417

  Yu, Bing ^a   Zheng, Yan ^a   Nettleton, Jennifer A ^a   Alexander, Danny ^b   Coresh, Josef ^c   Boerwinkle, Eric ^a,d  

^a UNIVERSITY OF TEXAS   (United States)

^b METABOLON INC   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1, 5 ANHYDROSORBITOL; ANTIHYPERTENSIVE AGENT; CREATINE; EPIDERMAL GROWTH FACTOR RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDICAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PYROGLUTAMIC ACID; UNCLASSIFIED DRUG; 1,5-ANHYDROGLUCITOL; BIOLOGICAL MARKER; DEOXYGLUCOSE;

ADULT; AFRICAN AMERICAN; ARTICLE; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; INCIDENCE; KIDNEY FUNCTION; LIMIT OF DETECTION; LINEAR REGRESSION ANALYSIS; LIQUID CHROMATOGRAPHY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; MERCURY SPHYGMOMANOMETER; METABOLITE; METABOLOMICS; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SMOKING; SURVIVAL; SYSTOLIC BLOOD PRESSURE; BLOOD; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; EPIDEMIOLOGY; ETHNOLOGY; KIDNEY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PROCEDURES; RENAL INSUFFICIENCY, CHRONIC; STATISTICAL MODEL; TIME; UNITED STATES;

AFRICAN AMERICANS; BIOMARKERS; CHROMATOGRAPHY, LIQUID; CREATINE; CROSS-SECTIONAL STUDIES; DEOXYGLUCOSE; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; INCIDENCE; INDICAN; KIDNEY; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; METABOLOMICS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PYRROLIDONECARBOXYLIC ACID; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TIME FACTORS; UNITED STATES;

EID: 84923773052     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.11971113     Document Type: Article

References (46)

1. Meguid El Nahas A, Bello AK: Chronic kidney disease: The global challenge. Lancet 365: 331–340, 2005.
2. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 298: 2038–2047, 2007.
3. Kottgen A, Russell SD, Loehr LR, Crainiceanu CM, Rosamond WD, Chang PP, Chambless LE, Coresh J: Reduced kidney function as a risk factor for incident heart failure: The atherosclerosis risk in communities (ARIC) study. J AmSocNephrol 18: 1307–1315, 2007.
4. Alonso A, Lopez FL, Matsushita K, Loehr LR, Agarwal SK, Chen LY, Soliman EZ, Astor BC, Coresh J: Chronic kidney disease is associated with the incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. Circulation 123: 2946–2953, 2011.
5. Wattanakit K, Folsom AR, Selvin E, Coresh J, Hirsch AT, Weatherley BD: Kidney function and risk of peripheral arterial disease: Results from the Atherosclerosis Risk in Communities (ARIC) Study. J Am Soc Nephrol 18: 629–636, 2007.
6. Astor BC, Coresh J, Heiss G, Pettitt D, Sarnak MJ: Kidney function and anemia as risk factors for coronary heart disease and mortality: The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 151: 492–500, 2006.
7. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT; Chronic Kidney Disease Prognosis Consortium: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative metaanalysis. Lancet 375: 2073–2081, 2010.
8. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D: Predictors of new-onset kidney disease in a community-based population. JAMA 291: 844–850, 2004.
9. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G; National Kidney Foundation: National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 139: 137–147, 2003.
10. Fox CS, Gona P, Larson MG, Selhub J, Tofler G, Hwang SJ, Meigs JB, Levy D, Wang TJ, Jacques PF, Benjamin EJ, Vasan RS: A multimarker approach to predict incident CKD and microalbuminuria. J Am Soc Nephrol 21: 2143–2149, 2010.
11. Astor BC, Shafi T, Hoogeveen RC, Matsushita K, Ballantyne CM, Inker LA, Coresh J: Novel markers of kidney function as predictors of ESRD, cardiovascular disease, and mortality in the general population. Am J Kidney Dis 59: 653–662, 2012.
12. Keller BJ, Martini S, Sedor JR, Kretzler M: A systems view of genetics in chronic kidney disease. Kidney Int 81: 14–21, 2012.
13. Weiss RH, Kim K: Metabolomics in the study of kidney diseases. Nat Rev Nephrol 8: 22–33, 2012.
14. Zhao YY: Metabolomics in chronic kidney disease. Clin Chim Acta 422: 59–69, 2013.
15. Zhao YY, Cheng XL, Wei F, Bai X, Tan XJ, Lin RC, Mei Q: Intrarenal metabolomic investigation of chronic kidney disease and its TGF-b1 mechanism in induced-adenine rats using UPLC Q-TOF/HSMS/MS(E). J Proteome Res 12: 692–703, 2013.
16. Malet-Martino M, Holzgrabe U: NMR techniques in biomedical and pharmaceutical analysis. J Pharm Biomed Anal 55: 1–15, 2011.
17. Rhee EP, Clish CB, Ghorbani A, Larson MG, Elmariah S, McCabe E, Yang Q, Cheng S, Pierce K, Deik A, Souza AL, Farrell L, Domos C, Yeh RW, Palacios I, Rosenfield K, Vasan RS, Florez JC, Wang TJ, Fox CS, Gerszten RE: A combined epidemiologic and metabolomic approach improves CKD prediction. J Am Soc Nephrol 24: 1330–1338, 2013.
18. Qi S, Ouyang X, Wang L, Peng W, Wen J, Dai Y: A pilot metabolic profiling study in serum of patients with chronic kidney disease based on (1) H-NMR-spectroscopy. Clin Transl Sci 5: 379–385, 2012.
19. Toyohara T, Akiyama Y, Suzuki T, Takeuchi Y, Mishima E, Tanemoto M, Momose A, Toki N, Sato H, Nakayama M, Hozawa A, Tsuji I, Ito S, Soga T, Abe T: Metabolomic profiling of uremic solutes in CKD patients. Hypertens Res 33: 944–952, 2010.
20. Shah VO, Townsend RR, Feldman HI, Pappan KL, Kensicki E, Vander Jagt DL: Plasma metabolomic profiles in different stages of CKD. Clin J Am Soc Nephrol 8: 363–370, 2013.
21. Duranton F, Lundin U, Gayrard N, Mischak H, Aparicio M, Mourad G, Daure`s JP, Weinberger KM, Argile´s A: Plasma and urinary amino acidmetabolomic profiling in patients with different levelsof kidney function. Clin J Am Soc Nephrol 9: 37–45, 2014.
22. Tarver-Carr ME, Powe NR, Eberhardt MS, LaVeist TA, Kington RS, Coresh J, Brancati FL: Excess risk of chronic kidney disease among African-American versus white subjects in the United States: A population-based study of potential explanatory factors. J Am Soc Nephrol 13: 2363–2370, 2002.
23. ARIC Investigators: The Atherosclerosis Risk in Communities (ARIC) Study: Design and objectives. The ARIC investigators. Am J Epidemiol 129: 687–702, 1989.
24. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604–612, 2009.
25. Bash LD, Coresh J, Köttgen A, Parekh RS, Fulop T, Wang Y, Astor BC: Defining incident chronic kidney disease in the research setting: The ARIC Study. Am J Epidemiol 170: 414–424, 2009.
26. Ohta T, Masutomi N, Tsutsui N, Sakairi T, Mitchell M, Milburn MV, Ryals JA, Beebe KD, Guo L: Untargeted metabolomic profiling as an evaluative tool of fenofibrate-induced toxicology in Fischer 344 male rats. Toxicol Pathol 37: 521–535, 2009.
27. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E: Integrated, nontargeted ultrahigh performance liquid chromatography/ electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem 81: 6656–6667, 2009.
28. Zheng Y, Yu B, Alexander D, Mosley TH, Heiss G, Nettleton JA, Boerwinkle E: Metabolomics and incident hypertension among blacks: The atherosclerosis risk in communities study. Hypertension 62: 398–403, 2013.
29. Zheng Y, Yu B, Alexander D, Manolio TA, Aguilar D, Coresh J, Heiss G, Boerwinkle E, Nettleton JA: Associations between metabolomic compounds and incident heart failure among African Americans: The ARIC Study. Am J Epidemiol 178: 534–542, 2013.
30. Haroun MK, Jaar BG, Hoffman SC, Comstock GW, Klag MJ, Coresh J: Risk factors for chronic kidney disease: A prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol 14: 2934–2941, 2003.
31. Westfall PH, Young SS: Resampling-Based Multiple Testing: Examples and Methods for P-Value Adjustment, New York, John Wiley & Sons, 1993.
32. Grambsch PM, Therneau TM: Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81: 515–526, 1994.
33. Goek ON, Döring A, Gieger C, Heier M, Koenig W, Prehn C, Römisch-Margl W, Wang-Sattler R, Illig T, Suhre K, Sekula P, Zhai G, Adamski J, Köttgen A, Meisinger C: Serum metabolite concentrations and decreased GFR in the general population. Am J Kidney Dis 60: 197–206, 2012.
34. Ahmad S: L-carnitine in dialysis patients. Semin Dial 14: 209–217, 2001.
35. Flanagan JL, Simmons PA, Vehige J, Willcox MD, Garrett Q: Role of carnitine in disease. Nutr Metab (Lond) 7: 30, 2010.
36. Powis SH, Trowsdale J: HLA and disease. Br J Clin Pract 45: 116–120, 1991.
37. Kortmann W, van Agtmael MA, van Diessen J, Kanen BL, Jakobs C, Nanayakkara PW: 5-Oxoproline as a cause of high anion gap metabolic acidosis: An uncommon cause with common risk factors. Neth J Med 66: 354–357, 2008.
38. Humphreys BD, Forman JP, Zandi-Nejad K, Bazari H, Seifter J, Magee CC: Acetaminophen-induced anion gap metabolic acidosis and 5-oxoprolinuria (pyroglutamic aciduria) acquired in hospital. Am J Kidney Dis 46: 143–146, 2005.
39. Anderson ME: Glutathione: An overview of biosynthesis and modulation. Chem Biol Interact 111-112: 1–14, 1998.
40. Jackson AA, Badaloo AV, Forrester T, Hibbert JM, Persaud C: Urinary excretion of 5-oxoproline (pyroglutamic aciduria) as an index of glycine insufficiency in normal man. Br J Nutr 58: 207–214, 1987.
41. Wu G, Fang YZ, Yang S, Lupton JR, Turner ND: Glutathione metabolism and its implications for health. J Nutr 134: 489–492, 2004.
42. Santangelo F, Witko-Sarsat V, Drüeke T, Descamps-Latscha B: Restoring glutathione as a therapeutic strategy in chronic kidney disease. Nephrol Dial Transplant 19: 1951–1955, 2004.
43. Chen X, Carystinos GD, Batist G: Potential for selective modulation of glutathione in cancer chemotherapy. ChemBiol Interact 111-112: 263–275, 1998.
44. Buse JB, Freeman JL, Edelman SV, Jovanovic L, McGill JB: Serum 1,5-anhydroglucitol (GlycoMark): A short-term glycemic marker. Diabetes Technol Ther 5: 355–363, 2003.
45. Dungan KM, Buse JB, Largay J, Kelly MM, Button EA, Kato S, Wittlin S: 1,5-anhydroglucitol and postprandial hyperglycemia asmeasured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 29: 1214–1219, 2006.
46. Boudonck KJ, Mitchell MW, Német L, Keresztes L, Nyska A, Shinar D, Rosenstock M: Discovery of metabolomics biomarkers for early detection of nephrotoxicity. Toxicol Pathol 37: 280–292, 2009.